PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Department of Refractory Viral Infections, National Center for Global Health and Medicine (NCGM) Research Institute, Tokyo, Japan. kmaeda@ri.ncgm.go.jp.\', \'Department of Clinical Sciences, Kumamoto University Hospital, Kumamoto, Japan.\', \'Center of Clinical Sciences, NCGM, Tokyo, Japan.\', \'AIDS Clinical Center, NCGM, Tokyo, Japan.\', \'Sysmex Corporation, Hyogo, Japan.\', \'Department of Refractory Viral Infections, National Center for Global Health and Medicine (NCGM) Research Institute, Tokyo, Japan.\', \'JCHO Kumamoto General Hospital, Kumamoto, Japan.\', \'Tokyo Metropolitan Institute for Public Health, Tokyo, Japan.\', \'Department of Refractory Viral Infections, National Center for Global Health and Medicine (NCGM) Research Institute, Tokyo, Japan. hmitsuya@hosp.ncgm.go.jp.\', \'Department of Clinical Sciences, Kumamoto University Hospital, Kumamoto, Japan. hmitsuya@hosp.ncgm.go.jp.\', \'Experimental Retrovirology Section, HIV and AIDS Malignancy Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. hmitsuya@hosp.ncgm.go.jp.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.1038/s41598-021-01930-y
?:doi
?:hasPublicationType
?:journal
  • Scientific reports
is ?:pmid of
?:pmid
?:pmid
  • 34819514
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.533
?:rankingScore_hIndex
  • 122
is ?:relation_isRelatedTo_publication of
?:title
  • Correlates of neutralizing/SARS-CoV-2-S1-binding antibody response with adverse effects and immune kinetics in BNT162b2-vaccinated individuals.
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all